Monitor for future data readouts or commercial expansion decisions based on ALOHA Program results; this collaboration may support broader MagIQ adoption if results are positive, but no immediate revenue impact is expected.
Price Chart
Executive Summary
Waldencast plc's Obagi Medical announced a collaboration with ProMD Health as part of its Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program to evaluate the clinical performance of Obagi® saypha® MagIQ™ across ProMD’s 17 multi-state practices. The partnership focuses on generating real-world evidence through structured evaluation, combining Obagi's protocols with ProMD's injector experience to assess patient outcomes and injection techniques.
Key Facts
- Obagi Medical (a Waldencast brand) launched a collaboration with ProMD Health under the ALOHA Program to evaluate Obagi® saypha® MagIQ™, a hyaluronic acid filler.
- ProMD Health operates 17 multi-location aesthetic practices and was selected for its clinical excellence and provider network.
- The program will collect standardized data on clinical efficacy, patient experience, and post-care protocols to build real-world evidence.
- No financial terms, revenue impact, or deal value were disclosed in the press release.
- Obagi® saypha® MagIQ™ uses MACRO Core Technology for stable, three-dimensional hyaluronic acid delivery with consistent performance.
Financial Impact
No financial impact disclosed; collaboration is evaluative and non-commercial at this stage
Risk Factors
- No guarantee that the evaluation will lead to commercial adoption or revenue generation.
- Results may not demonstrate sufficient clinical or patient benefit to justify broader rollout.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258991 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $0.7500 | awaiting T+5 | — | — |
Oct 15, 2026 11d ago | 6-K | $0.7500 | awaiting T+5 | — | — |
Oct 15, 2026 11d ago | 15-12G | $0.7500 | awaiting T+5 | — | — |
Oct 14, 2026 13d ago | EFFECT | $0.8100 | awaiting T+5 | — | — |
Oct 14, 2026 13d ago | EFFECT | $0.8100 | awaiting T+5 | — | — |
Oct 14, 2026 13d ago | EFFECT | $0.8100 | awaiting T+5 | — | — |
Sep 28, 2026 28d ago | Press Release | $0.9277 $0.8794 | ▲ +5.21% | ▲ +7.15% | — |
Sep 24, 2026 4w ago | 6-K | $1.03 $0.8794 | ▲ +14.62% | ▲ +14.40% | — |
Sep 24, 2026 4w ago | Press Release | $1.03 $0.8794 | ▲ +14.62% | ▲ +14.40% | — |
Sep 14, 2026 6w ago | Press Release | $1.18 $1.10 | ▲ +6.78% | ▲ +6.89% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers